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Targeted Disruption of Leukotriene B4 Receptors BLT1 and
BLT2: A Critical Role for BLT1 in Collagen-Induced Arthritis
in Mice1
Wen-Hai Shao,*† Annalisa Del Prete,*‡ Cheryl B. Bock,§ and Bodduluri Haribabu2*†
Leukotriene B4 mediates diverse inflammatory diseases through the G protein-coupled receptors BLT1 and BLT2. In this study,
we developed mice deficient in BLT1 and BLT2 by simultaneous targeted disruption of these genes. The BLT1/BLT2 double-
deficient mice developed normally and peritoneal exudate cells showed no detectable responses to leukotriene B4 confirming the
deletion of the BLT1/BLT2 locus. In a model of collagen-induced arthritis on the C57BL/6 background, the BLT1/BLT2/ as well
as the previously described BLT1/ animals showed complete protection from disease development. The disease severity cor-
related well with histopathology, including loss of joint architecture, inflammatory cell infiltration, fibrosis, pannus formation, and
bone erosion in joints of BLT1/BLT2/ animals and a total absence of disease pathology in leukotriene receptor-deficient mice.
Despite these differences, all immunized BLT1/ and BLT1/BLT2/ animals had similar serum levels of anti-collagen Abs
relative to BLT1/BLT2/ animals. Thus, BLT1 may be a useful target for therapies directed at treating inflammation associated
with arthritis. The Journal of Immunology, 2006, 176: 6254–6261.
R heumatoid arthritis (RA)3 is a chronic inflammatory dis-ease involving multiple joints and remains an autoim-mune disease of unknown etiology (1). Collagen-induced
arthritis (CIA) is a model for RA that is induced in susceptible
mouse strains by intradermal immunization with collagen type II
(CII) emulsified in a complete adjuvant (2, 3). The significance of
this model is that CII is the major constituent protein of cartilage
in diarthrodial joints, the predominant site of inflammation in RA.
In addition, the pathogenesis of CIA is in many ways similar to
that of RA as both RA and CIA are characterized by an intense
synovitis accompanied by erosions of cartilage and subchondral
bone by a pannus-like tissue (4). Susceptibility to CIA was con-
sidered to be MHC class-linked (H-2q and H-2r) as only DBA/1
(H-2q) and B10.RIII (H-2r) mice, among the most commonly used
strains, are susceptible to CIA (5). However, recently Campbell et
al. (6, 7) modified the immunization procedure and showed that
clinically and histologically similar CIA may be induced in
C57BL/6 (B6) mice. In addition to serving as a valuable tool to
study immunity to CII, the CIA model has proven equally useful
to investigate inflammatory joint injury and led to the development
of novel TNF-based therapies for human RA (8, 9).
Leukotriene B4 (LTB4; (5S,12R)-dihydroxy-6,14-cis-8,10-
trans-eicostatetraenoic acid) is one of the most potent chemoat-
tractants of leukocytes (10). LTB4 promotes inflammation by stim-
ulating CD11b up-regulation and adhesion of leukocytes,
emigration of leukocytes from the bloodstream, neutrophil activa-
tion leading to respiratory burst, degranulation, and release of en-
zymes (10). In addition, LTB4 can alter transcriptional profiles
resulting in proinflammatory amplification circuits (11, 12). These
processes have been implicated in the pathogenesis of a variety of
diseases such as atherosclerosis, asthma, allergic encephalomyeli-
tis, psoriasis, and inflammatory bowel disease (13, 14). A role for
LTB4 in RA was suggested by several observations over the past
two decades. LTB4 levels in synovial fluids from patients with
active RA were 5-fold higher relative to synovial fluids from os-
teoarthritis (15, 16). Neutrophils from RA patients undergoing
methotrexate therapy displayed both acute and chronic suppression
of LTB4 synthesis ex vivo (17). LTB4 receptor antagonists were
found to inhibit CIA in mice (18, 19). Mice deficient in 5-lipoxy-
genase-activating protein (FLAP), and as a consequence in LTB4
synthesis, were partially protected from developing CIA (20).
Two distinct G protein-coupled receptors, BLT1 and BLT2,
likely mediate the effects of LTB4 in different cell types (21, 22).
BLT1 is a high-affinity receptor expressed in a variety of leuko-
cytes including neutrophils, monocyte/macrophages, eosinophils,
mast cells, and activated T lymphocytes. BLT2 is a low-affinity
LTB4 receptor more widely expressed in human tissues. Of interest,
high levels of BLT2 mRNA expression were observed in actively
inflamed synovial tissue from patients with RA where as leukocytes
infiltrating synovial fluid predominantly expressed BLT1 mRNA in
these patients (23). Previously described BLT1/ mice allowed
the determination of a critical role for BLT1 in atherosclerosis and
airway hyperresponsiveness (11, 24, 25). However, the physiolog-
ical role of BLT2 is unknown. The genes for BLT1 and BLT2 are
adjacent to each other in both mouse and human genomes and are
separated by only 4 kb of intergenic region. Moreover, the pro-
moter of the BLT1 gene is within the coding region of BLT2 (26).
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Because crossing of single knockout animals cannot be used to
create a double knockout of BLT1 and BLT2, we have generated
BLT1/BLT2 double-deficient mice by directly targeting both re-
ceptors. In this study, we tested the BLT1/ and the BLT1/
BLT2/ mice in the CIA model. The results showed that disrup-
tion of BLT1 alone is sufficient to offer complete protection of
mice from developing arthritis, whereas anti-CII Ab levels in
BLT1/ and BLT1/BLT2/ were similar to the
BLT1/BLT2/ mice.
Materials and Methods
Targeting construct and generation of BLT1/BLT2 double-
deficient mice
The previously described BLT1 targeting construct was modified to target
both BLT1 and BLT2 genes (27). The BAC clone containing the mouse
BLT1 and BLT2 genes was mapped by restriction analysis, and a 4.5-kb
fragment 10 aa upstream of the BLT2 coding region was subcloned into the
NotI-XhoI sites of the pBluescript vector. The EGFP expression cassette
was PCR amplified from pEGFP-N2 (BD Clontech) and inserted in-frame
after the first 10 aa of the BLT2 coding region at the XhoI site of the 4.5-kb
fragment. This fragment with EGFP included was used to replace the long
arm of the previously described targeting construct (27). The resulting final
construct pWSGB was 16 kb in length. The mock construct which served
as a positive control for PCR screening of the embryonic stem (ES) cell
clones was the same as previously described (27). AK7 (129S4/SvJaeSor)
ES cells (107) were electroporated with 25 g of NotI-linearized WSGB-
DNA. The transfected cells were grown in DMEM with 200 g/ml G418
and 2  106 M ganciclovir for 10 days. Surviving clones were tested for
recombination using a neomycin-coding sequence primer—tcgcagcg-
catcgccttctatcg—and a primer from the 3 end of BLT1 gene external to the
knockout construct—gctgggagtcatcaacaagcactc. Of the eight positive
clones, four were expanded and the genotypes were confirmed by Southern
blot analysis with 10–20 g of DNA using the 0.9-kb probe (BglII/BamHI
fragment) external to the 3 end of the knockout construct. Two undiffer-
entiated clones were individually microinjected into C57BL/6J blastocysts
and transferred into pseudopregnant C57BL/6 mice. Chimeric mice gen-
erated from two individual cell clones resulted in immediate germline
transmission and the F1 (C57BL/6 and 129 SvJ) offspring were used to
establish the mouse colonies. Genotyping was performed using Southern
blotting with the same probe indicated above or more routinely using a
three primer PCR with the primers 1) atgtctgtctgctaccgtcc, 2) aggtgcagca
caagtgtggc, and 3) cagctcgaccaggatggg. All mice were housed in a specific
pathogen-free barrier facility. Mice were 8–12 wk old at the time of use.
All studies and procedures were approved by the Animal Care and Use
Committee of University of Louisville Research Resources Center.
Generation and analysis of 300.19 cell lines expressing murine
BLT1 and BLT2
Murine (m) BLT1 and BLT2 were stably expressed to similar levels in a
mouse pre-B cell line, 300.19 (28). Hemagglutinin-tagged mBLT1 or
mBLT2 cDNAs (20 g) in the eukaryotic expression vector pRK-5 were
transfected into 300.19 cells by electroporation, selected for G418 resis-
tance, and stained with 12CA5 Ab and cells expressing the hemagglutinin
epitope on the surface were sorted by flow cytometry. Cells expressing
similar levels of the receptor were analyzed for functional receptor expres-
sion. For calcium mobilization, 3 106 cells were washed and loaded with
1.0 M Indo-1 AM for 30 min at 37°C as previously described (29). Cal-
cium traces were recorded in a Hitachi fluorescence spectrometer (model
F-2500) with an excitation wavelength of 355 nm and an emission wave-
length of 405 nm. Calcium mobilization in 4-h zymosan A-elicited peri-
toneal lavage cells containing over 80% neutrophils was also measured
essentially by the same procedure.
Northern blot analysis
Mouse neutrophils and macrophages were isolated from the peritoneal la-
vage after 4 and 72 h of zymosan A treatment, respectively. Total RNA
isolation was performed as described according to the manufacturer’s di-
rections (RNeasy; Qiagen). Twelve micrograms of total RNA from mouse
spleen, liver, neutrophils, and macrophages were denatured, electropho-
resed on 1.2% formaldehyde-agarose gel, and transferred to nylon mem-
branes (Hybond-N; Amersham Biosciences). The membranes were hy-
bridized with 32P-labeled open reading frame (ORF) of mouse BLT1,
BLT2, cell death-inducing DFF45-like effector B (CIDE-B), and -actin at
42°C overnight in an ULTRAhyb hybridization buffer (Ambion). The
membranes were washed in 2 standard saline citrate phosphate/EDTA,
0.1% SDS, followed by washing in 0.1 standard saline citrate phosphate/
EDTA, 0.1% SDS at 55°C for 1 h, and subjected to autoradiography.
Mice used in CIA experiments
The previously described BLT1/ mice (27) have been backcrossed onto
the B6 background for seven generations and the experimental control
mice for this group were purchased from The Jackson Laboratory. The
BLT1/BLT2/ mice were backcrossed onto B6 for nine generations.
The BLT1/BLT2/ mice were then intercrossed to generate three groups
of BLT1/BLT2/, BLT1/BLT2/, and BLT1/BLT2/ littermate mice.
All mice were 8 wk of age at the time of experimentation, and were age
matched.
Induction and assessment of arthritis
CFA was prepared by mixing 100 mg of heat-killed Mycobacterium tu-
berculosis (H37Ra; Difco Laboratories) in 20 ml of IFA (Sigma-Aldrich)
(6). An emulsion was formed by dissolving 2.0 mg/ml chick CII (CII;
Sigma-Aldrich) overnight at 4°C in 10 mM acetic acid and combining it
with an equal volume of CFA. CII solution and the emulsion with CFA
were always freshly prepared. Mice were injected i.d. at the base of the tail
with a total of 100 l of emulsion containing 100 g of CII and 250 g of
M. tuberculosis. The same injection was repeated at day 21; however, due
to toughening of the skin at the base of the tail, booster injections were
distal to the primary injection site.
Clinical and histological assessment of arthritis
All mice were examined two to three times per week for the initial visual
appearance of arthritis after immunization. Arthritis of each individual limb
was graded using the following scoring system: 0, normal; 1, apparent
swelling and redness limited to individual digits; 2, swelling in more than
one joint; 3, severe redness and swelling of the entire paw including digits;
and 4, maximally inflamed limb with involvement of multiple joints. The
maximum score per mouse was 16. Mice were scored as arthritic if more
than one paw had a score 2. The thickness of the hind paws was mea-
sured using a dial gauge caliper (Mitsutoyo). At the end of the experiment,
the rear paws and joints were removed, fixed, decalcified, and paraffin
embedded. Joint sections (5 m) were stained with H&E and examined for
the histological changes of inflammation, pannus formation, cartilage, and
bone damage. Arthritic changes in the ankle were scored as previously
described: 0, normal; 1, weak leukocyte infiltration but no erosion; 2, mod-
est infiltration and weak erosion; 3, severe infiltration and invasion of
bones; and 4, loss of bone integrity (30).
Determination of serum anti-collagen Ab levels by ELISA
Blood was collected by cardiac puncture. After clotting at room tempera-
ture for 1 h, the samples were kept overnight at 4°C and the serum was
collected by centrifuging at 13,000 rpm for 5 min. ELISAs for Abs to CII
were performed as described in the Arthrogen-CIA manual (Arthrogen-
CIA kit; Chondrex). In brief, precoated plates were washed and incubated
with blocking buffer for 2 h at room temperature. Serum at a 1/37,500
dilution was added to each well. Plates were incubated at 4°C overnight,
washed six times and incubated with peroxidase-conjugated goat anti-
mouse IgG for 2 h at room temperature, and then washed six times. Per-
oxidase activity was then determined following the addition of orthophe-
nylenediamine chromagen in urea H2O2 buffer for 30 min by determining
the OD at 490 nm. Each sample was tested in duplicate and the mean value
was recorded.
Immunohistochemistry
Immunohistochemistry was performed on deparaffinized slides using the
traditional primary/secondary Ab-peroxidase technique. Briefly, paraffin-
embedded sections were dewaxed and hydrated, Ag was retrieved with
Tris/EDTA buffer, and endogenous peroxidase was blocked by incubating
with 0.3% H2O2 for 10 min. Sections were then block with 3% BSA and
following with primary Ab and corresponding HRP-secondary Ab staining.
Color was developed by treatment with 3,3-diaminobenzidine (Sigma-
Aldrich) and sections were counterstained with hematoxylin.
Results
mBLT2 is a functional LTB4 receptor
Although the BLT2 gene has been identified from several sources,
the functional activity of BLT2 in primary cells is yet to be dem-
onstrated. To determine whether the mBLT2 is a functional LTB4
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receptor, we generated stable 300.19 cell lines expressing this re-
ceptor. Fig. 1 shows dose-response profiles of LTB4-induced cal-
cium mobilization in cells expressing mBLT1 or mBLT2. Consis-
tent with the results from cell lines expressing human BLT1 and
BLT2, these cells activated dose-dependent calcium release with
mBLT1 showing at least 10-fold more sensitivity to LTB4 than
mBLT2.
Generation of BLT1/BLT2 double-deficient mice
To delete both BLT1 and BLT2 genes simultaneously, we used a
modified targeting vector from the one used to generate BLT1-
deficient mice (27). In this vector, the entire region between amino
acid no. 10 of BLT2 through amino acid 316 of BLT1 was deleted
and replaced with the PGK-neomycin (PGK-Neo) cassette (Fig.
2a). In addition, the sequence encoding an in-frame fusion of the
GFP coding region was inserted following codon no. 10 of BLT2.
BLT1/BLT2/ mice were generated essentially following the
same protocols described for BLT1/ mice (27). Fig. 2b shows a
Southern blot of BamHI- and XhoI-digested DNA from the three
genotypes. The BLT1/BLT2/ littermate lanes (/) show the
expected 5.3-kb band and the homozygous lanes (/) show the
6.5-kb mutant band. The heterozygous (/) lanes show both
the wild-type (WT) and mutant bands. BLT1/BLT2/ mice were
born at the expected Mendelian ratios and showed no overt devel-
opmental or morphological abnormalities. Three primer PCRs to
identify the junction of the BLT2 and GFP fusion in the double-
deficient mice (Fig. 2c, left) or the neo gene and BLT1 at the 3 end
(Fig. 2c, right) were routinely used to determine the genotypes
from the genomic DNA isolated from tail biopsies.
Analysis of lymphoid tissues found no gross alterations in the
size of the thymus, spleen, or lymph nodes between BLT1/
BLT2/ and WT littermates. The number and distribution of
CD4 and CD8 T lymphocytes, or B220 B lymphocytes found
within the spleen, peripheral lymph nodes, mesenteric lymph
nodes, or within the blood were similar in BLT1/BLT2/ and con-
trol animals (data not shown). In addition, no significant differences
were found in numbers of circulating lymphocytes, monocytes, neu-
trophils, or eosinophils or in serum IgG and IgM levels between the
BLT1/BLT2/ and BLT1/BLT2/ mice (data not shown).
Analysis of mBLT2 gene expression
To confirm that the mutation disrupted the LTB4 receptor expres-
sion and not other chemoattractant receptors, zymosan-elicited
peritoneal exudate cells (over 80% neutrophils) were analyzed for
calcium mobilization. Both LTB4 and platelet activating factor
(PAF)-induced calcium mobilization in cells from littermate
BLT1/BLT2/ animals (Fig. 3a). In contrast, cells from the
BLT1/BLT2/ animals showed no calcium mobilization in re-
sponse to LTB4 but equivalent responses to PAF compared with
cells from BLT1/BLT2/ mice.
FIGURE 1. mBLT2 is a functional LTB4 receptor. The 300.19 cells
expressing the mBLT1 or mBLT2 were loaded with Indo-1 and release of
intracellular calcium was measured as described in Materials and Methods.
Response to increasing concentrations of LTB4 was monitored in real time.
Dose-response curves of percent calcium release for mBLT1 and mBLT2
were shown. Data represent average measurements from three different
calcium traces for each concentration.
FIGURE 2. Targeted disruption of mouse BLT1/
BLT2. a, Genomic locus of BLT1 and BLT2, targeting
vector, and the recombinant mutant genomic locus.
Coding region of the BLT1 and BLT2 gene is indicated
as solid boxes. Six kilobases of the coding region and
the untranscribed region between BLT1 and BLT2
ORF was replaced with PGK-neo cassette in the target-
ing vector. An enhanced GFP (EGFP) expression cas-
sette was inserted in-frame 30 bp downstream of BLT2
ORF and upstream of the neo gene. The final construct
contained homology arms of 4.5 and 1.5 kb. A BglII-
BamHI fragment served as an external probe for South-
ern blot analysis of genomic DNA from ES cells and
mouse tails. b, Southern blotting showing correct tar-
geting and germline transmission of the mutated BLT1/
BLT2 gene. Genomic DNA samples prepared from F2
offspring were digested with BamHI and XhoI, sepa-
rated on 0.75% agarose gels, blotted onto nylon mem-
branes, and hybridized with the 32P-labeled, 0.9-kb Bg-
lII-BamHI fragment. The genotypes of the mice are
indicated above the lanes. c, A three-primer PCR was
designed to identify the WT, heterozygous, and ho-
mozygous mutant alleles at the BLT2/GFP junction
(left panel). The previously described three-primer PCR
methods used for screening BLT1-deficient mice was
also run occasionally to confirm the genotype (right
panel). The PCR and Southern blotting methods gave
the same in all cases tested.
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Northern blot analysis of RNA from spleen, liver, peritoneal
neutrophils, and macrophages showed strong expression of
mBLT1 in neutrophils, and relatively lower levels of expression in
macrophages in the BLT1/BLT2/ mice, but no expression in the
BLT1/BLT2/ mice (Fig. 3b). Data also showed weak BLT1
expression in the spleen of BLT1/BLT2/ mice (Fig. 3b). Hy-
bridization with the mBLT2 ORF probe (Fig. 3b) or BLT2 5-UTR
or 3-UTR (data not shown) failed to show any mBLT2 expression
in any of the tissues studied. An overlapping divergently tran-
scribed gene, CIDE-B in this locus showed normal liver-specific
expression in both the BLT1/BLT2/ and BLT1/BLT2/ mice
(Fig. 3b).
Although BLT2 was expressed in a wide variety of tissues, in-
cluding liver and spleen in humans, we did not detect any GFP
expression in these tissues either in the BLT1/BLT2/ or in
BLT1/BLT2/ mice. Although flow cytometry revealed weak
GFP expression in platelets, we could not detect any functional
activity of BLT2 in these or other cells (data not shown).
BLT1/ and BLT1/BLT2/ mice are completely resistant to CIA
Mice of the H-2q (DBA/1J) background are highly susceptible to
CIA whereas mice of the H-2b (B6) are resistant. However, mod-
ification of the immunization procedure results in high incidence
of CIA in B6 background mice (6). In two separate preliminary
experiments, using the same method, we successfully induced ar-
thritis in B6 strain mice (data not shown). To determine the role of
LTB4 receptors in arthritis, we set up two different study groups:
the BLT1/ mice were set up together with control B6 (BLT1/
BLT2/) mice and the littermate offspring from BLT1/BLT2/
breeders (BLT1/BLT2/, BLT1/BLT2/, and BLT1/BLT2/)
constituted a second group. The arthritis symptoms in BLT1/
BLT2/, BLT1/, BLT1/BLT2/, and BLT1/BLT2/ mice
were studied after immunization with CII on day 0 and a boost
with CII on day 21. Mice were examined weekly after the first
immunization and every 2–3 days after the boost for signs of de-
veloping arthritis. The severity of the arthritis was assessed using
a visual scoring system standardized under our laboratory exper-
imental conditions (Fig. 4a). The BLT1/BLT2/ animals devel-
oped clinical signs of arthritis with an incidence of 37 and 60% by
38 and 25 days, respectively (Fig. 4, b and c). Because male and
female mice developed arthritis with comparable incidence, only
the total number of mice is shown. The average cumulative clinical
score and the swelling measured as paw thickness are shown in
Fig. 4, d–g. The clinical appearance of the swollen joints, the
range of severity, and the progression to severe swelling was sim-
ilar to that observed in DBA/1 mice. None of the BLT1/ or
BLT1/BLT2/ developed any signs of arthritic disease as com-
pared with the BLT1/ control mice (Fig. 4). The intermediate
incidence and severity of arthritis in the BLT1/BLT2/ mice in
this group indicated a possible gene dosage affect in the CIA model
(Fig. 4, c, e, and g).
Histological features of immunized BLT1/BLT2/, BLT1/,
and BLT1/BLT2/ mice
An observer unaware of the genotype of the animals scored the
histopathology of hind limb knee joints. The severity of disease as
determined by the histological features correlated with the ob-
served visual scores (Figs. 5, a and b, and 6). None of the
BLT1/ and BLT1/BLT2/ mice had any evidence of arthritis
upon histological examination (Figs. 5, c–f, and 6). Pannus forma-
tion, fibrillation of the articular surface, and eventual ankylosis are
hallmarks of RA. Mild to moderate pannus and fibrillation of the
articular surface were common in the BLT1/BLT2/ mice (Fig.
5, g–i). In contrast, none of the BLT1/ or BLT1/BLT2/ mice
showed any sign of pannus formation or fibrillation of the cartilage
(data not shown).
Immune response against CII in BLT1/ and BLT1/BLT2/ mice
A high level of anti-CII Ab generation accompanies the develop-
ment of disease in the CIA model (3). To investigate whether the
disease-free incidence of arthritis in BLT1/ and BLT1/
BLT2/ mice was due to the lack of an Ab response to type II
collagen, the anti-CII-specific levels of IgG in the serum were
determined at the termination of the CIA experiment. Anti-CII Ab
levels were similar in BLT1/ mice and in BLT1/ and BLT1/
BLT2/ mice (Fig. 6).
Inflammatory cell infiltration in B6-CIA synovitis
To determine the type and extent of inflammatory cell infiltration
occurring during disease development, histopathological examina-
tion and immunohistochemical staining of synovial tissues were
performed. Fig. 7 shows the typical inflammatory cell infiltration
found in BLT1/ animals and complete absence of these cells in
the BLT1/ animals. Examination of arthritic tissue sections at
FIGURE 3. Expression analysis of
mBLT2. a, Calcium mobilization of peritoneal
neutrophils from BLT1/BLT2/ and BLT1/
BLT2/mice. Calcium flux was monitored in
Indo-1-loaded, zymosan-elicited peritoneal
neutrophils stimulated with 100 nM LTB4 and
100 nM PAF as indicated. Each tracing repre-
sents an analysis of 3 106 cells from a single
mouse with the indicated genotype, and the
data shown is representative of at least three
each of BLT1/BLT2/ or BLT1/BLT2/
animals. b, RNA blot analysis of mBLT1 and
mBLT2. Fifteen micrograms of total RNA was
isolated from spleen, liver, peritoneal neutro-
phils, or macrophages were separated on 1.0%
agarose gels and transferred to nylon mem-
branes. The RNA blot was sequentially hybrid-
ized with BLT1, BLT2, -actin, and CIDE-B
cDNA probes, and exposed to x-ray film for
3 h to overnight after washing. Bottom,
Ethidium bromide-stained agarose gel shows
comparable RNA loading in each lane.
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higher magnification showed a predominant neutrophil-based in-
flammation (Fig. 7b) but also some lymphocytes (arrows) and
macrophages (arrowhead). Immunohistochemical analysis with
Gr-1 and CD3 Abs confirmed these observations (Fig. 8), whereas
the BLT1/ mice showed no detectable immunostaining with any
of these markers.
Discussion
The deletion of the BLT1/BLT2 genes reported in this study reveals
a potential role for these receptors in inflammatory arthritis. The
BLT1/BLT2/ mice were viable, developed normally, and dis-
played no overt behavioral or morphological defects. The number
and development of leukocyte subpopulations were normal in
BLT1/BLT2/ mice. The Southern and PCR analysis of mice
and the demonstration that these mice lacked the expression of a
functional LTB4 receptor in peritoneal lavage cells clearly estab-
lishes the generation of a leukotriene receptor double-deficient
mouse line.
The studies reported here demonstrate that expression of
mBLT2 in cell lines results in a low-affinity receptor that responds
to LTB4, suggesting that mBLT2 is indeed an LTB4 receptor. Al-
though BLT2 was identified several years ago, its expression pat-
tern in different tissues remains unclear. Although macrophages
and to some extent neutrophils were suggested to express BLT2
(22, 31) and BLT2 mRNA was detected in a wide variety of human
tissues, the expression of BLT2 in mouse tissues is unknown.
Tager and Luster (32) suggested they could not detect BLT2 ex-
pression in mice. Our results are consistent with these findings that
BLT2 mRNA was not detectable in murine tissues by Northern
blot analysis. An examination of relative abundance of human and
murine leukotriene receptor cDNA clones in public expressed se-
quence tag databases is also consistent with this observation. Al-
though human BLT1 and BLT2 are represented at similar abun-
dance (43 and 41 clones, respectively), the mBLT1 is more
frequently identified than mBLT2 (22 vs 3 clones). These obser-
vations suggest that while the mBLT2 gene is indeed expressed, the
level of transcription of mBLT2 gene is very weak relative to human
BLT2. Based on the design of the construct, we expected the GFP
expression to represent the native BLT2 expression pattern. Al-
though the absence of GFP expression in most mouse tissues in the
knockout/knockin mouse generated here may not represent the true
expression pattern of BLT2, it is consistent with the failure to
detect any BLT2 mRNA. Further biochemical as well as functional
FIGURE 4. Resistance of BLT1/ mice and
BLT1/BLT2/ to CIA. Age- and sex-matched B6
mice were immunized with chicken CII emulsified in
CFA at day 0 and boosted at day 21. Mice were scored
blind to the knowledge of the genotype of the animals
every 2–3 days. a, Representative assignments of clin-
ical scores for CIA-B6 model. b and c, Incidence of
arthritis: mice were considered arthritic when inflam-
mation was observed in any paw with clinic score 2,
and number of arthritic mice in each group is shown as
a percentage. d and e, Clinical score of arthritis: paws
from each mouse were scored every 2–3 days. The
scores from four paws were then combined for each
mouse, and total severity score for the group was di-
vided by the number of arthritic mice to obtain an
average severity score. f and g, Paw thickness: hind
paw swelling was evaluated with spring-loaded cali-
per during the course of the disease. Average change
in paw thickness increase obtained for each mouse by
subtracting the baseline of paw thickness before the
first immunization. SD is indicated with error bars.
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studies with BLT2 single-deficient mice are needed to precisely
define the mBLT2 function.
CIA has been the most widely used animal model for studying
the pathogenesis of human RA and for screening novel therapeutic
compounds. Although B6 mice are known to be resistant to CIA,
it was the secondary but not the primary immune response to col-
lagen that is defective in these mice (33). Campbell et al. (6) first
reported that CIA could be induced in B6 at an incidence ap-
proaching that of congenic DBA/1 mice using an altered immuni-
zation protocol. Following the same procedure, with increasing the
CFA concentration and administering both the primary and boost
injection i.d., we could induce 40–70% incidence of arthritis in B6
mice. It should be noted that this level of incidence is relatively
low compared with 70–100% incidence routinely observed for
CIA in the DBA strain. However, the severity scores reported here
are comparable to most studies on arthritis in DBA mice (34).
These data suggest that the method of immunization but not the
MHC haplotype might be a critical determinant of CIA incidence
in B6 mice. The precise mechanisms whereby immunization with
CII leads to a chronic arthritis are not known; however, data have
shown that the CIA model is absolutely dependent on B cells and
is significantly dependent on CD4 T cell involvement (35–38).
Our results of comparable levels of anti-CII Ab indicate the normal
functioning of B cells in the BLT1/ and BLT1/BLT2/ mice.
It should also be noted that levels of anti-CII Abs in the WT an-
imals also did not correlate with the disease incidence i.e., most
animals had similar levels of anti CII Ab but only some (40–60%)
did get the disease. This may be related to an activation event that
requires BLT1. In this regard, the function of LTB4 as a chemoat-
tractant for activated CD4 and CD8 T cells expressing BLT1
(24, 39) may play an essential role in the B6-CIA model, because
substantial numbers of CD3 cells were detected in the synovial
tissue of the BLT1/BLT2/ arthritic mice but not in the
BLT1/ mice.
Synovial fluid rich in inflammatory cells, in particular neutro-
phils, characterizes human RA (40). Neutrophils have been con-
sidered a key player in the articular and extra-articular manifesta-
tions of the disease. This appears to be the case for the CIA model
in B6 mice as well. A variety of cells have been suggested as
contributing to the initiation and progression of the immune re-
sponse in rheumatoid synovium, including neutrophils, T cells,
macrophages, fibroblasts, synoviocytes, and endothelial cells. Al-
though the interplay between these cell types and the specific site
of BLT1 activity remains to be established, lack of T lymphocytes
in synovial cavity of the immunized BLT1 mice suggests an early
role of BLT1 in disease development. Moreover, complete absence
of neutrophil recruitment in BLT1/ mice, and the known activ-
ity of BLT1 in neutrophils suggest that BLT1 could also play a
direct role in neutrophil recruitment to the arthritic joints.
Multiple studies over the past two decades have suggested a role
for arachidonic acid-derived lipid mediators in human RA (41, 42).
Moreover, mice deficient in cyclooxygenase 2 (COX2), cytosolic
phospholipase A2, and FLAP are all protected from CIA (20, 43–
45). Although COX2 inhibitors were in extensive use for human
RA treatment until recently, cardiovascular side effects led to a
drastic reduction in use of these compounds (46, 47). Leukotrienes
were recently demonstrated to be effective promoters of athero-
sclerosis (14). Inhibition of COX2 could result in increased ara-
chidonic acid production, a substrate for 5-LO pathway leading to
increased leukotriene generation that might account for the ob-
served side effects of COX2 treatment. Thus, leukotrienes could
offer an alternate target for treating inflammatory arthritis.
The current results of complete inhibition of CIA in BLT1-de-
ficient B6 mice need to be considered in the context of several
earlier studies using LTB4 biosynthesis inhibitors or receptor an-
tagonists in mice and in human RA clinical trials. First, several
studies have shown that antagonists of BLT1 offer significant but
not complete reduction of CIA development in mice (18, 19). In
addition, in a model of IL-18 enhanced CIA in the DBA strain, a
role for LTB4 was established and inhibition of CIA induction by
MK-886, a FLAP inhibitor, was observed (48). Moreover, in a
DBA model of CIA partial protection from arthritis was observed
in FLAP-deficient mice (20). The partial protection observed with
FIGURE 5. Histopathology of CIA in mice. Massive changes in the knee
joints of the BLT1/BLT2/ (a and b) but not in BLT1/ (c and d) and
BLT1/BLT2/ (e and f ) mice. Joint bones (tibia, tarsus), synovial joint tissue,
and cartilage are shown. No histopathological changes in BLT1/BLT2/
mice and BLT1/ mice were observed. Histopathological changes of the WT
mice were evaluated in terms of proliferation of synovial cells, necrosis/fibro-
sis (g), ankylosis (h), pannus (i), and the total severity of arthritic changes,
including the destruction of cartilage and bone. Magnification is indicated at
the lower right corner of each micrograph.
FIGURE 6. Histopathological scores and anti-CII IgG levels in CIA
mice. BLT1/BLT2/, BLT1/, and BLT1/BLT2/ mice are repre-
sented by f, u, and  columns, respectively. Histopathological evalua-
tions were described in Materials and Methods. Both BLT1/ and BLT1/
BLT2/ mice produced comparable levels of anti-CII Abs relative to the
WT mice both with and without disease, but the BLT1/, and BLT1/
BLT2/ mice did not show any sign of disease both in clinical and his-
topathological views. The number of animals tested in each group is
indicated.
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receptor antagonists as well other inhibitors and mouse models
may be related to the incomplete targeting of the BLT1 and the
differences in the DBA vs B6 model.
Several leukotriene antagonists and biosynthesis inhibitors have
been used in clinical trials for human RA, but none have been
approved for the treatment of RA (49, 50). Although the elements
of inflammatory response are similar, murine CIA has limitations
in modeling human arthritis, including the absence of rheumatoid
factor as well as lack of clear mechanisms for the initiation of
disease in humans (5). There are several potential explanations for
the clinical failure of past leukotriene-based drugs for treatment of
arthritis. Because all of the leukotriene antagonists are selected
based on assays of neutrophil function, they may not have com-
plete blocking activity on other cell types such as T cells. Another
reason might be related to genetic variation in human populations.
Although most of the inbred mouse models have shown strong
leukotriene effects in CIA models, only subsets of human RA pa-
tients might benefit from the leukotriene antagonist-based thera-
pies. Although the current study has shown complete protection
against CIA in BLT1-deficient mice, the known expression pattern
of BLT2 in human synovial tissues (23) suggests another potential
difference in leukotriene involvement in human RA vs murine
CIA. Despite these limitations, studies on RA patients might ben-
efit from reinvestigation of dose, efficacy, and pharmacokinetics of
the previously tested compounds as well as direct examination of
the involvement of this pathway in human RA.
In summary, this study has described the generation of BLT1/
BLT2/ mice and defined a critical role for BLT1 in CIA. Be-
cause the loss of BLT1 alone is sufficient to offer complete pro-
tection against CIA, a role for BLT2 in this model could not be
established. However, in a number of other models, including ath-
erosclerosis and asthma, loss of BLT1 only offers partial protection
or delays the progression of the disease (11, 25). The BLT1/
BLT2/ mice will be a valuable resource in further studies in
these and other models of inflammatory diseases.
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